Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #884

    I could find more enjoyable things to read @Raffles 😉 I am curious to find out how long this dispute has been going on already...was it already there when the hexacd38 deal was done..

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #885

      I find it hard to find merit for JNJ's case in this document, but then again, i am not a lawyer, and JNJ has a whole army of lawyers...

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #886

        I think the case came up when JNJ paid royalty for Q220 …

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #887

          According to 14.4 (A) the case must have been running for a while: "Subject to Clauses 14.5 and 14.6, if any Dispute has not been resolved by good faith negotiations or mediation between the Parties pursuant to Clauses 14.2 or 14.3 above or the Parties have not agreed to mediate, then the Parties shall settle the Dispute by submitting the matter to binding arbitration pursuant".

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #888

            So first negotiation, then mediation and then binding arbitration.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #889

              I doubt that Solsen. Arbitration is the last step and the step that will make it public.Surely they would have wanted to avoid that

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #890

                & Bulder typs faster 😉

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #891

                  Evaluate Vantage Esmo 2020 – J&J goes for broke with lung cancer bispecific - https://www.evaluate.com/vantage/articles/events/conferences/esmo-2020-jj-goes-broke-lung-cancer-bispecific

                  1 Reply Last reply
                  0
                  • DarvinD Offline
                    DarvinD Offline
                    Darvin
                    wrote on sidst redigeret af
                    #892

                    Like El I’m not a lawyer. Har læst artiklerne igennem (især 2, 3, 6 og 7) og man skal sandelig holde tungen lige i munden. Som jeg læser det har RBC ret. Det er svært at læse det anderledes end at Genmab har ret i begge forhold. Ingen reduktion af royalty og ret til royalty i den forlængede licensperiode. Men det står også klart at det bliver juristeri og argumentation omkring årsag. Virker helt klart som et, måske for vovet, forsøg på, fra JNJ’s side at tryne Genmab. Den skulle nok aldrig være

                    1 Reply Last reply
                    0
                    • DarvinD Offline
                      DarvinD Offline
                      Darvin
                      wrote on sidst redigeret af
                      #893

                      endt i Arbitration.

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #894

                        Kan godt undre lidt at det kom så vidt.

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #895

                          Når det kommer dertil tror jeg godt Jan kan være svær at rokke, altså vi er vel flere herinde der ikke finder det urimeligt, hvis nu Genmab skal afgive 1% royalty til Halozymes og Janssen dermed slipper med 4% - hvis altså Halo får 5%.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #896

                            ADC Therapeutics IPO kurs 34

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #897

                              Just a moment...

                              favicon

                              (www.firstwordpharma.com)

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #898

                                Det undrer også mig. Men når JW har udtalt at patentforlængelse giver roalty og at Genmab ikke skal betale til HALO så kan han vel næppe godkende anden aftale uden selv at komme i klemme. Derfor konflikten uden afgørelse i mindelighed.

                                1 Reply Last reply
                                0
                                • D Offline
                                  D Offline
                                  Doublo
                                  wrote on sidst redigeret af
                                  #899

                                  Jeg tror at JW er overbevist om, at han har ret, det er en principsag. Hvis han giver sig uden at få det afprøvet en gang for alle, så mister J&J respekten. Der er forøvrigt flere både finanshus og analytiker der slår til lyd for, at der er tale om en overreaktion, det vil slet ikke få konsekvenser der berettiger det store kursfald. Men spændende er det.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #900

                                    Genedata and Genmab Reach New Milestone in Digitalizing Translational and Clinical Research https://www.genedata.com/news/details/genmab-digitalizes-translational-and-clinical-research

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #901

                                      Doublo- jeg tror du har ret. Genmab sender et signal til JNJ og andre nuværende samt kommende samarbejdspartnere. Vi er store og stærke nu, og Big Pharma skubber os ikke rundt i manegen som det passer dem...

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #902

                                        Nogen der har en idé om tidshorizonten for sådan en sag?

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #903

                                          I Børsen i går stod der godt et år hvis der ikke findes et forlig

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger